🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Industrials Sector SEC Filings — September 10, 2026

The 7 filings reveal a bifurcated capital landscape within S&P 500 Industrials. Two major debt offerings dominate: Parker-Hannifin's ~$4.4B refinancing for its Filtration Group acquisition and 3M's €1.5B note issuance for general corporate purposes, signaling active balance sheet management post-M&A and opportunistic refinancing. The most compelling signal is the massive $55.4M+ insider purchase by Republic Services' 10% owner Cascade Investment, indicating strong conviction in the waste management sector. Conversely, a small director sale at Parker-Hannifin and a routine tax-withholding at General Dynamics provide no material bearish signals. The absence of forward-looking guidance or period-over-period comparisons in these filings limits trend analysis, but the capital allocation patterns suggest a focus on debt optimization and insider confidence in select names. Two filings (ADP and Uber) were excluded as they fall outside the S&P 500 Industrials sector focus.

5 high priority 2 medium 7 total filings
· daily

US Material Events SEC 8-K Filings — September 10, 2026

This Material Events Monitor digest covers 50 filings from September 10, 2026, revealing a market landscape defined by aggressive capital deployment through M&A and debt financing, alongside significant corporate restructuring and leadership transitions. The most critical developments include a $1.9B acquisition of ACV Auctions by Copart at a 45% premium, a $200M acquisition of BioCircuit by Axogen, and a $224M deal for Swarmer to acquire Ratel Robotics, signaling a strong appetite for growth through acquisition in the tech-enabled services and defense sectors. However, this is counterbalanced by severe distress signals, including a major restructuring at CVD Equipment (halving its workforce) and a 10.8% revenue decline at 1-800-FLOWERS leading to a goodwill impairment. A notable portfolio-level pattern is the heavy reliance on debt markets for financing, with over $5.4B in new debt issued across just four companies (Williams, Group 1, Autodesk, Public Storage), while insider activity remains largely absent, offering limited conviction signals. The digest identifies a bifurcated market where well-capitalized firms are pursuing aggressive growth, while others are retrenching, restructuring, or facing existential challenges.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — September 10, 2026

This batch of 24 filings from Dow 30 constituents is dominated by insider transactions and routine corporate actions, with a notable concentration of activity at NIKE. The most significant development is the massive stock gift by NIKE Director Travis Knight (2.85M shares), which, combined with the company's annual meeting revealing 32% dissent on executive compensation, signals potential governance concerns and a possible shift in the founding family's involvement. A clear pattern of insider selling via 10b5-1 plans emerges across multiple mega-caps, including Visa's General Counsel, JPMorgan's Head of HR, and Apple's GC, which, while pre-planned, creates a bearish sentiment overhang. The only capital markets activity is 3M's €1.5B debt offering for general corporate purposes, indicating a focus on liability management. Overall, the filings suggest a cautious posture from corporate insiders and a period of capital allocation stability, with NIKE being the primary stock to watch for ownership structure changes.

21 high priority 3 medium 24 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 10, 2026

The 8 filings in this stream reveal a bifurcated landscape: a wave of voluntary, non-distressed listing transfers from NYSE to the Texas Stock Exchange (TXSE) by three energy MLPs (Sunoco LP, Energy Transfer LP, USA Compression Partners, LP) contrasts sharply with acute, fundamental distress signals from two micro-cap biotechs (20/20 Biolabs, iSpecimen) facing Nasdaq delisting for equity deficiencies. A third entity, the Bitwise Dogecoin ETF, is undergoing a complete liquidation and shutdown, representing a total capital loss for remaining holders. The TXSE transfers, while not distress events, create a temporary dislocation and signal a strategic shift in listing venue preferences. The core distress signals are concentrated in the healthcare/life sciences sector, where both 20/20 Biolabs and iSpecimen are critically undercapitalized, with negative equity positions and imminent compliance deadlines. A positive outlier is Global Interactive Technologies, which swiftly resolved a delinquency notice, demonstrating strong financial controls. The overarching theme is a 'hollowing out' of marginal, speculative assets (crypto ETF, cash-poor biotechs) while stable, cash-flowing energy partnerships execute a strategic realignment.

8 high priority 8 total filings
· daily

Global High-Priority Regulatory Events — September 10, 2026

This digest covers 25 filings from September 10, 2026, with a heavy concentration on corporate distress and restructuring events. A notable cluster involves three energy infrastructure companies (Sunoco LP, Energy Transfer LP, USA Compression Partners) voluntarily delisting from the NYSE to transfer to the Texas Stock Exchange, signaling a potential trend toward regional exchange migration. The insolvency and bankruptcy theme is prominent, with Shilpa Medicare's subsidiary entering CIRP, VXL Instruments' resolution plan approved with near-total shareholder dilution, and JSW Infrastructure acquiring a loss-making rail company through the IBC process. Several small-cap biotech and tech companies face Nasdaq delisting risks, including 20/20 Biolabs and iSpecimen, both with severe equity deficiencies. On the positive side, Global Interactive Technologies resolved its filing delinquency, and Ryan Cohen continued accumulating GameStop shares. The most significant M&A event is ARC Group Acquisition Corp's $1.09 billion deal to acquire a Malaysian financing company, while SurgePays executed a creative asset sale with a put option to address its Nasdaq compliance issues. Overall, the filings reflect a market environment with high distress among small caps, strategic exchange migrations, and continued SPAC activity.

25 high priority 25 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — September 10, 2026

The 19 filings for September 10, 2026, reveal a consumer discretionary sector dominated by insider activity, particularly at NIKE, where a mix of director stock awards and executive sales under 10b5-1 plans, alongside a massive gift from Director Knight, paints a complex picture. A significant governance signal emerges from NIKE's annual meeting, where 32% of shareholders voted against executive compensation, indicating notable dissent. At Marriott, three members of the founding family disposed of 2 million shares each, a coordinated move that warrants scrutiny. Meanwhile, Starbucks' CEO had shares withheld for taxes, and eBay's CEO executed a series of sales under a plan. The lack of period-over-period financial comparisons, forward-looking guidance, or capital allocation data in these filings limits trend analysis, making insider transactions the primary actionable signal. The overall theme is one of mixed insider sentiment, with no clear sector-wide bullish or bearish consensus, but several high-conviction signals from key insiders at major companies.

19 high priority 19 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — September 10, 2026

The three filings from the S&P 500 Healthcare sector reveal a mixed picture of defensive stability and selective insider activity. Elevance Health, a managed care giant, reaffirmed its 2026 guidance, signaling confidence in its operational outlook despite a neutral market reaction, with a key focus on its benefit expense ratio. In contrast, Bristol-Myers Squibb saw a notable insider sale by its Chief Medical Officer, a bearish signal that may reflect personal portfolio management or a cautious view on the company's near-term prospects. Vertex Pharmaceuticals reported an insider stock award, a routine compensation event that suggests no immediate concern. The overarching theme is one of sector divergence: large-cap managed care is projecting steady profitability, while big pharma faces headwinds from insider selling and pipeline uncertainty. The lack of period-over-period comparisons in these filings limits trend analysis, but the insider activity and reaffirmed guidance provide actionable signals for portfolio positioning.

2 high priority 1 medium 3 total filings
· daily

US Executive Compensation Proxy SEC Filings — September 10, 2026

The seven DEF 14A filings reveal a period of significant corporate governance and structural change, with a clear focus on board refreshment, executive compensation alignment, and post-transaction restructuring. Key trends include a shift toward virtual-only shareholder meetings, with 3 of 7 companies opting for virtual formats, and a notable increase in board independence and refreshment, as seen at Resources Connection and Applied Industrial Technologies. The most material development is GeoVax Labs' proposal to issue shares representing over 55% of its outstanding stock, a high-dilution event that warrants immediate attention. In the fund sector, two filings (Northern Lights Fund Trust IV and Advisors Series Trust) highlight a trend of change-of-control transactions triggering new advisory agreements and fund reclassifications, with no expected changes to fees or strategies. Audit fee trends show a mixed picture, with Consumers Bancorp seeing a 21.3% decline in audit fees, while other companies' fee data was not disclosed. Overall, the filings suggest a market focused on governance efficiency and strategic repositioning, with limited direct financial performance data, but clear signals of management's forward-looking optimism in certain sectors.

7 high priority 7 total filings
· daily

US IPO Pipeline SEC S-1 Filings — September 10, 2026

The IPO pipeline is active with three new SPAC filings (Elevation Acquisition Group, Allarity Acquisition Corp.) and a traditional IPO (Hometown Financial Group), alongside two resale registrations (OLB GROUP, Rafex Gold Corp.) and two debt exchange filings (Broadcom, OptimumBank Holdings) that are routine and have minimal market impact. The most critical development is the Hometown Financial Group IPO, which represents a mutual-to-stock conversion offering up to 8.5 million shares at $10, providing a rare opportunity for retail and plan participants to invest in a newly public community bank. The SPAC filings signal continued blank-check activity, though investor appetite remains uncertain. Rafex Gold Corp. stands out as a high-risk microcap with no developed public market and an arbitrarily set offering price, while OLB GROUP's resale filing highlights significant dilution risk from multiple warrant series. Overall, the pipeline is diverse but lacks blockbuster names, with most filings being small-cap or non-operational entities.

7 high priority 7 total filings
· daily

US SEC Trading Suspension Halt Orders — September 10, 2026

The eight filings for September 10, 2026, reveal a bifurcated landscape in US trading suspensions. A dominant theme is the voluntary mass exodus of four energy and infrastructure partnerships (Sunoco LP, Energy Transfer LP, USA Compression Partners, and SunocoCorp LLC) from the NYSE to the Texas Stock Exchange (TXSE), all effective October 2-5, 2026. This coordinated move, while neutral in sentiment and low in materiality for each individual company, signals a strategic realignment toward a regional exchange, likely driven by cost or governance preferences. In stark contrast, two high-risk biotech/life sciences companies (20/20 Biolabs and iSpecimen) face imminent delisting threats due to severe equity deficiencies, while the Bitwise Dogecoin ETF is voluntarily liquidating entirely. The only positive development is Global Interactive Technologies, which resolved its Nasdaq delinquency. The period-over-period data highlights a clear sector divergence: energy partnerships are stable and voluntarily migrating, while micro-cap biotechs are struggling with capital adequacy, creating a 'haves vs. have-nots' dynamic in exchange listings.

8 high priority 8 total filings
· daily

US Executive Officer Management Changes SEC — September 10, 2026

The 37 filings reveal a period of significant leadership flux, with a notable cluster of CFO departures and appointments, often tied to restructuring or strategic realignment. While most changes are routine, several high-materiality events stand out, including the mass departure of five senior officers at Two Harbors Investment Corp. and a major restructuring at CVD Equipment Corporation. Period-over-period data is sparse, but forward-looking statements from TransMedics and Candel Therapeutics provide positive catalysts. Insider activity is limited, but the lack of disclosed disagreements in most departures suggests orderly transitions. A key theme is the use of executive appointments to drive specific strategic initiatives, such as STAAR Surgical's commercial push and Huntington Bancshares' succession planning. The overall sentiment is neutral, with pockets of positive and negative signals requiring close monitoring.

37 high priority 37 total filings
· daily

US Corporate Board Director Changes SEC Filings — September 10, 2026

This batch of 37 filings reveals a high volume of board room changes across sectors, including a notable cluster of significant CFO and board transitions. A key trend is the prevalence of restructurings and leadership overhauls at smaller, struggling companies, such as the complete C-suite departure at Two Harbors Investment Corp (TWOD) and a major business pivot at CVD Equipment Corporation (CVV). Conversely, several larger firms are making strategic appointments, such as TransMedics (TMDX) hiring a CFO from GE HealthCare and Insulet (PODD) seeing two long-tenured directors depart. Sentiment across the portfolio is predominantly neutral, but two events stand out as highly material: the Five Senior Officer departures at Two Harbors (negative) and the major restructuring at CVD Equipment (negative). Forward-looking data from Candel Therapeutics and TransMedics provides clear catalysts, such as a planned BLA submission and a reiterated growth guidance, respectively. A critical warning signal emerges from NIKE, where 32% of shareholders voted against executive compensation, indicating significant governance concerns. The high concentration of CFO changes (Fortrea, Village Farms, New Fortress Energy, TransMedics, CVD Equipment, Whitehawk, SCYNEXIS, Versus Systems, Golden Minerals, AptarGroup) suggests a broader trend of financial leadership rotation.

37 high priority 37 total filings
· daily

USA Insider Trading Pulse — September 10, 2026

The September 10, 2026, insider trading pulse reveals a market characterized by starkly divergent insider behavior: significant, high-conviction buying by major stakeholders in select value and growth names contrasts with systematic, 10b5-1 plan-driven selling by C-suite executives at high-flying tech companies. The most notable capital deployment is a $55.4M open-market purchase by a 10% owner of Republic Services, signaling deep conviction in the waste management sector. Conversely, a coordinated wave of insider selling is evident at Twist Bioscience, where the CEO, CAO, and SVP of HR all sold shares at $122.62, and at JFrog Ltd, where the CEO and CRO sold over $2.6M combined. The data also shows a cluster of insider buying at micro-cap companies like Cybin Inc. and Grace Therapeutics, where executives invested over $1M each, suggesting a bet on upcoming catalysts. The overall picture is one of a bifurcated market: large-cap insiders are taking profits, while value-oriented and micro-cap insiders are signaling confidence through open-market purchases.

49 high priority 1 medium 50 total filings
· daily

US Merger & Acquisition SEC Filings — September 10, 2026

The September 10, 2026 M&A digest reveals a dynamic landscape: two SPACs (ARC Group, Three Lions) are executing on their capital-raising and business combination mandates, while two healthcare-focused companies (Tarsus, National Healthcare) are actively reshaping their portfolios through strategic acquisitions and divestitures. SurgePays' divestiture of its ClearLine platform for $27.5M in preferred stock, coupled with a put option, is a critical move to regain Nasdaq compliance, highlighting the pressure on small caps to maintain listing standards. The period-over-period data shows a clear trend of companies using M&A to pivot toward higher-growth or core assets, with Tarsus' acquisition of Alkeus Pharmaceuticals adding a Phase 3 asset with significant regulatory designations. However, the mixed sentiment on ARC Group and SurgePays underscores execution and dilution risks. Overall, the digest points to a bifurcated market: strategic buyers with cash are acquiring clinical-stage assets for long-term growth, while distressed or non-compliant companies are using asset sales to shore up balance sheets. The most critical development is ARC Group's $1.09 billion acquisition of Firstborn Top Capital, which, if completed, would be a transformative cross-border deal, but its success hinges on shareholder approval and regulatory clearance.

6 high priority 6 total filings
· monthly

US Pre-Market SEC Filings Roundup — September 10, 2026

Overnight filings reveal a market bifurcated between aggressive capital deployment and insider profit-taking. Axogen's $200M acquisition of BioCircuit Technologies and Indaptus' $24M raise signal continued M&A and financing activity in medtech, while Elevance Health's reaffirmed guidance provides stability in managed care. Insider activity is notably heavy in bitcoin miners (CleanSpark, TeraWulf) and Dell Technologies, where Silver Lake entities are systematically reducing stakes at ~$515-519/share, suggesting potential valuation concerns at current levels. Biohaven's partial clinical hold introduces regulatory overhang in neurology, partially offset by a new licensing deal with SK Biopharmaceuticals. The Equitable-Corebridge merger advances with quantified synergies, while YPF's debt tender offer and H World's $470M bond pricing reflect active liability management. SPAC activity (Elevation Acquisition IPO, XCF Global meeting postponement) and a 22.7% activist stake in Abits Group highlight continued special situations. Overall, the tape is constructive but selective, with capital flowing to growth and consolidation while insiders in high-flying sectors take profits.

34 high priority 16 medium 50 total filings
· daily

DHS Homeland Security Contracts — September 09, 2026

The single contract in this digest, a $110.6 million firm-fixed-price delivery order from DHS/CBP to Astrophysics Inc., underscores a focused civilian homeland security investment theme: border security technology modernization. With zero defense-related awards, the signal is purely civilian, driven by DHS priorities for non-intrusive inspection systems. The highest-conviction signal is the 84% outlay rate ($92.8M), indicating strong execution and cash flow realization, but the full-and-open competition and absence of set-asides suggest pricing pressure. A key risk is the firm-fixed-price structure over a multi-year performance period (through 2027, potential to 2033), which carries execution risk if costs escalate.

1 total filings
· daily

New Federal Contractors — September 09, 2026

This digest covers two large, non-defense civilian agency contracts totaling $218 million in obligations, with zero defense exposure and an average signal strength of 6/10. The dominant agency theme is DHS/CBP border security technology, driven by Astrophysics Inc.'s $110.6 million delivery order for non-intrusive inspection systems, which offers strong executed cash flow (84% outlayed) and multi-year revenue visibility through 2027-2033. The second contract, Magellan Healthcare Inc.'s $107.4 million EAP award to HHS, is neutral and aging, with a non-competitive, fixed-price structure and low outlay (12% funded) suggesting limited near-term materiality. Key risks include pricing pressure from full competition on the Astrophysics award and potential contract concentration risk for Magellan Healthcare in federal healthcare services.

2 total filings
· daily

Significant Contract Modifications ($10M+) — September 09, 2026

The digest covers two civilian contracts totaling $218.0 million, with zero defense-related awards, underscoring a non-DOD procurement focus. The dominant theme is homeland security, led by a $110.6 million Astrophysics Inc. delivery order from DHS/CBP for non-intrusive inspection systems, which carries a bullish signal due to 84% outlay and multi-year revenue visibility through 2033. A second $107.4 million Magellan Healthcare contract for HHS employee assistance services is neutral, with execution risk from its non-competitive award and fixed-price structure. Key risk is the absence of defense exposure in a period where CR uncertainty typically pressures civilian agencies, while the Astrophysics award signals durable border security spending.

2 total filings
· daily

Contract Deobligations Alert — September 09, 2026

The two contracts totaling $218 million are entirely civilian, with zero defense exposure, underscoring a non-DOD procurement theme. The dominant signal is a $110.6 million DHS/CBP award to Astrophysics Inc. for inspection systems, which is 84% outlayed and provides multi-year revenue visibility through 2027—our highest-conviction bullish signal. The second contract, a $107.4 million non-competitive HHS award to Magellan Healthcare Inc., is neutral due to its 2014-2022 performance period, low outlay rate, and high fixed-price execution risk. Key watch items include DHS border security budget allocations and potential recompetition of the Magellan contract.

2 total filings
· daily

Contract Option Exercises — September 09, 2026

The September 9, 2026 contract option exercise stream totals $218.0 million across two civilian awards, with zero defense-related contracts. The dominant theme is civilian agency investment in specialized services: DHS/CBP's $110.6 million award to Astrophysics Inc. for non-intrusive inspection systems (84% outlayed, strong execution) and HHS's $107.4 million Employee Assistance Program contract to Magellan Healthcare Inc. (non-competitive, low outlay). The highest-conviction signal is Astrophysics Inc.'s multi-year revenue visibility through 2027 (potential 2033), though its firm-fixed-price structure and full competition introduce execution and pricing risk. Key watch item: Magellan Healthcare's contract ended in 2022, raising recompetition and concentration risk for its federal portfolio.

2 total filings